英格兰HPV疫苗接种与宫颈癌筛查按种族的效果:一项建模研究
该研究构建基于个体的HPV传播与疾病动态模型,参数取自Natsal-3、PHE、ARTISTIC和ONS,评估英格兰不同种族疫苗接种与筛查 uptake 差异对HPV相关癌症发病不平等的影响。模型预测,因少数族裔接种率较低,疫苗引入后20年亚洲女性宫颈癌发病率可达白人女性的2.5倍(95%CI 1.3-4.8),但随时间群体免疫将使差距缩小;提高少数族裔筛查 uptake 可在20年后实现发病平等。
要点
- 疫苗接种前,亚洲女性宫颈癌发病率是白人女性的1.7倍(95%CI 1.1-2.7)。
- 接种后20年,亚洲女性宫颈癌发病率可达白人女性2.5倍(95%CI 1.3-4.8)。
- 提高少数族裔疫苗接种女性筛查 uptake 可在接种20年后实现发病平等。
核心结论
- 模型提示英格兰引入HPV疫苗将先扩大已有的HPV相关癌症发病种族差异,部分因群体免疫不成比例地惠及接种率高的亚群。
- 随时间推移该差异将缩小,但鼓励提高少数族裔女性宫颈筛查 uptake 以在中期消除宫颈癌发病不平等。
- 作者建议在评估公共卫生规划对平等的影响时应考虑动态效应。
研究设计与样本
- 基于个体的HPV传播与疾病动态模型,参数来自Natsal-3的性行为数据、PHE的按种族疫苗与筛查 uptake 数据,并拟合ARTISTIC、PHE、Natsal-3的HPV患病率及ONS国家癌症登记处的HPV相关疾病发病率。
- 结局为英格兰所有女性年龄调整的HPV相关癌症(宫颈与非宫颈)发病率,考虑不同种族疫苗接种与筛查 uptake 的差异及随时间变化。
- 还模拟了三种旨在减少HPV相关疾病发病不平等的公共卫生干预:将黑人与亚洲女性的疫苗接种 uptake 提高至白人水平、2018年及以后满25岁女性的宫颈筛查、所有年龄女性的宫颈筛查。
主要发现
- 疫苗接种前(2008年前),英格兰少数族裔女性宫颈疾病负担不成比例,亚洲女性宫颈癌诊断可能性是白人女性的1.7倍(95%可信区间1.1-2.7),发病率为每10万女性22.8例 vs 13.4例。
- 因少数族裔HPV疫苗接种 uptake 较低,模型预测疫苗引入后20年亚洲女性宫颈癌发病率最高可达白人女性的2.5倍(95%CI 1.3-4.8),相当于每年额外增加10.8例(95%CI 10.1-11.5)。
- 随时间推移,群体免疫益处将从较大的白人亚群扩散,差异将缩小;提高少数族裔接种女性的宫颈筛查 uptake 可在HPV疫苗接种20年后实现发病平等。
临床怎么用
- 作者建议应鼓励提高少数族裔女孩的宫颈筛查 uptake,以在中期消除宫颈癌发病不平等。
- 作者建议在估计公共卫生规划对平等的影响时应考虑动态效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Health equality is increasingly being considered alongside overall health gain when assessing public health interventions. However, the trade-off between the direct effects of vaccination and herd immunity could lead to unintuitive consequences for the distribution of disease burden within a population. We used a transmission dynamic model of human papillomavirus (HPV) to investigate the effect of ethnic disparities in vaccine and cervical screening uptake on inequality in disease incidence in England. METHODS: We developed an individual-based model of HPV transmission and disease, parameterising it with the latest data for sexual behaviour (from National Survey of Sexual Attitudes and Lifestyles [Natsal-3]) and vaccine and screening uptake by ethnicity (from Public Health England [PHE]) and fitting it to data for HPV prevalence (from ARTISTIC, PHE, Natsal-3) and HPV-related disease incidence (from National Cancer Registry [ONS]). The outcome of interest was the age-adjusted incidence of HPV-related cancer (both cervical and non-cervical) in all women in England in view of differences and changes in vaccination and screening uptake by ethnicity in England, over time. We also studied three potential public health interventions aimed at reducing inequality in HPV-related disease incidence: increasing uptake in black and Asian females to match that in whites for vaccination; cervical screening in women who turn 25 in 2018 or later; and cervical screening in all ages. FINDINGS: In the pre-vaccination era, before 2008, women from ethnic minorities in England reported a disproportionate share of cervical disease. Our model suggests that Asian women were 1·7 times (95% credibility interval [CI] 1·1-2·7) more likely to be diagnosed with cervical cancer than white women (22·8 vs 13·4 cases per 100 000 women). Because HPV vaccination uptake is lower in ethnic minorities, we predict an initial widening of this gap, with cervical cancer incidence in Asian women up to 2·5 times higher (95% CI 1·3-4·8) than in white women 20 years after vaccine introduction (corresponding to an additional 10·8 [95% CI 10·1-11·5] cases every year). In time, we predict that herd immunity benefits will diffuse from the larger white sub-population and the disparity will narrow. Increased cervical screening uptake in vaccinated women from ethnic minorities would lead to rapid improvement in equality with parity in incidence after 20 years of HPV vaccination. INTERPRETATION: Our study suggests that the introduction of HPV vaccination in England will initially widen a pre-existing disparity in the incidence of HPV-related cancer by ethnicity, partly due to herd immunity disproportionately benefiting subgroups with high vaccination rates. Although in time this induced disparity will narrow, increasing cervical screening uptake in girls from ethnic minorities should be encouraged to eliminate the inequality in cervical cancer incidence in the medium term. We recommend that dynamic effects should be considered when estimating the effect of public health programmes on equality. FUNDING: Cancer Research UK.
引用
- Johnson HC, Lafferty EI, Eggo RM, et al. Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study. Lancet Public Health. 2017. PMID: 29307388. doi:10.1016/S2468-2667(17)30238-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。